DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/zb5rw3/pharmapoint_type) has announced the addition of the "PharmaPoint: Type 2 Diabetes - India Drug Forecast and Market Analysis to 2022" report to their offering.
PharmaPoint: Type 2 Diabetes - India Drug Forecast and Market Analysis to 2022. The type 2 diabetes market is mature and crowded with inexpensive generics.
Despite being marked by a late-stage pipeline filled with me-too drugs, this market will undergo substantial growth between 2012 and 2022, more than doubling over this period. The main drivers of growth will be the dramatic increase in disease prevalence and physicians' efforts to delay disease progression and reduce the costly burden of diabetic complications through the use of combination therapies and novel branded drugs. In the emerging markets in particular, uptake of branded drugs will increase due to rapid economic growth.
We anticipate that the type 2 diabetes market will not experience a fundamental shift in the classes of drugs that are preferred by physicians. Rapid uptake of drugs from the novel class of SGLT-2 inhibitors will occur; however, DPP-4 inhibitors and GLP-1 receptor agonists will continue dominating the noninsulin type 2 diabetes space. GLP-1 receptor agonists will experience the fastest growth of all classes (CAGR of 17%), due to their weight-loss effects and their novel once-weekly administration, which is preferable to the standard once- or twice-daily therapies.
The law in India contains certain provisions which allow for the entry of generic drugs despite patent expiration, such as low-cost generics for life-threatening diseases. This is now spilling over to other chronic diseases like diabetes. Recently, Merck's bid to prevent Indian drug maker Glenmark Pharmaceuticals from selling copycat forms of Januvia and Janumet has suffered a setback in India. Lack of clarity in the drug regulatory system and weak patent laws are a challenge for foreign multinational companies attempting to enter or expand in the Indian healthcare market.
Scope
- Overview of type 2 diabetes including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in India including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in India from 2012-2022.
- Analysis of the impact of key events as well the drivers and restraints affecting India type 2 diabetes market.
For more information visit http://www.researchandmarkets.com/research/zb5rw3/pharmapoint_type
About Research and Markets
Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
